Repligen (NASDAQ:RGEN) Shares Gap Up - Still a Buy?

Key Points

• Shares of Repligen Corporation gapped up from a previous close of $119.65 to open at $126.00 before trading at $130.24.
• Analyst ratings are mixed, with upgrades from Wolfe Research and Stephens to "outperform," while Evercore ISI has lowered their target price from $140.00 to $130.00.
• The biotechnology firm reported a quarterly EPS of $0.37, missing estimates, but revenue increased by 14.8% year-over-year.

Repligen Corporation (NASDAQ:RGEN - Get Free Report)'s share price gapped up before the market opened on Tuesday . The stock had previously closed at $119.65, but opened at $126.00. Repligen shares last traded at $130.24, with a volume of 259,027 shares changing hands.

Analyst Ratings Changes

RGEN has been the subject of several recent research reports. Wells Fargo & Company lowered their price objective on Repligen from $180.00 to $175.00 and set an "overweight" rating for the company in a research report on Wednesday. Wolfe Research raised Repligen from a "peer perform" rating to an "outperform" rating and set a $160.00 price objective for the company in a research report on Tuesday, April 29th. Stephens raised Repligen to an "overweight" rating and set a $160.00 price objective for the company in a research report on Tuesday, July 22nd. Royal Bank Of Canada raised their price objective on Repligen from $193.00 to $204.00 and gave the company an "outperform" rating in a research report on Wednesday. Finally, HC Wainwright reaffirmed a "buy" rating and issued a $180.00 price target on shares of Repligen in a research report on Monday, May 5th. Five investment analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus price target of $169.45.

Repligen Trading Down 1.1%

The stock has a 50-day simple moving average of $123.39 and a two-hundred day simple moving average of $136.49. The company has a debt-to-equity ratio of 0.27, a quick ratio of 5.79 and a current ratio of 6.79. The firm has a market cap of $6.51 billion, a PE ratio of -461.66, a price-to-earnings-growth ratio of 2.27 and a beta of 1.11.

Repligen (NASDAQ:RGEN - Get Free Report) last issued its earnings results on Tuesday, July 29th. The biotechnology company reported $0.37 earnings per share for the quarter, missing analysts' consensus estimates of $0.40 by ($0.03). Repligen had a positive return on equity of 4.65% and a negative net margin of 2.05%. The business had revenue of $182.37 million during the quarter, compared to analysts' expectations of $174.62 million. During the same period last year, the firm posted $0.40 EPS. Repligen's quarterly revenue was up 14.8% compared to the same quarter last year. As a group, sell-side analysts anticipate that Repligen Corporation will post 1.72 EPS for the current year.

Institutional Investors Weigh In On Repligen

A number of large investors have recently made changes to their positions in RGEN. Raiffeisen Bank International AG bought a new stake in shares of Repligen during the 4th quarter valued at about $29,000. Twin Tree Management LP bought a new stake in shares of Repligen during the 1st quarter valued at about $29,000. Itau Unibanco Holding S.A. bought a new stake in shares of Repligen during the 4th quarter valued at about $40,000. Signaturefd LLC grew its stake in shares of Repligen by 65.3% during the 1st quarter. Signaturefd LLC now owns 324 shares of the biotechnology company's stock valued at $41,000 after purchasing an additional 128 shares during the period. Finally, Center for Financial Planning Inc. grew its stake in shares of Repligen by 110.3% during the 1st quarter. Center for Financial Planning Inc. now owns 368 shares of the biotechnology company's stock valued at $47,000 after purchasing an additional 193 shares during the period. 97.64% of the stock is currently owned by institutional investors.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.